Výsledky vyhledávání - "Hoorn, J.W.A. van der"

Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials

Autor: Kühnast, S., Fiocco, M., Hoorn, J.W.A. van der, Princen, H.M.G., Jukema, J.W.

Publikováno v: European Journal of Pharmacology, 763, 48-63

Non-HDL-cholesterol is well recognised as a primary causal risk factor in cardiovascular disease. However, despite consistent epidemiological evidence for an inverse association between HDL-C and coronary heart disease, clinical trials aimed at raisi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6c7d5a245e65517c8f0828e9218edc9f
http://resolver.tudelft.nl/uuid:80d5ce79-8fee-40f1-a1eb-828bf010c239

Zobrazit plný text záznamu

Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes

Autor: Liang, W., Verschuren, L., Mulder, P., Hoorn, J.W.A. van der, Verheij, J., Dam, A.D. van, Boon, M.R., Princen, H.M.G., Havekes, L.M., Kleemann, R., Hoek, A.M. van den

Publikováno v: British Journal of Pharmacology, 22, 172, 5293-5305
British Journal of Pharmacology, 172(22), 5293-5305

BACKGROUND AND PURPOSE: Salsalate (salicylsalicylic acid) is an anti-inflammatory drug that was recently found to exert beneficial metabolic effects on glucose and lipid metabolism. Although its utility in the prevention and management of a wide rang

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::53f35d9b12b75f413a45985e23353689
http://resolver.tudelft.nl/uuid:fafad1b5-a599-463d-9bb9-238a8d340fd2

Zobrazit plný text záznamu

APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome

Autor: Hoek, A.M. van den, Hoorn, J.W.A. van der, Maas, A.C., Hoogen, R.M. van den, Nieuwkoop, A. van, Droog, S., Offerman, E.H., Pieterman, E.J., Havekes, L.M., Princen, H.M.G.

Publikováno v: Diabetes, Obesity and Metabolism, 6, 16, 537-544

Aims: This study aimed to investigate systematically (i) the appropriate dietary conditions to induce the features of the MetS in APOE*3Leiden.humanCholesteryl Ester Transfer Protein (E3L.CETP) mice and (ii) whether the response of this model to diff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b7284d2bda75aceb1d5732725eb1acca
http://resolver.tudelft.nl/uuid:c585fde4-f8c6-48f4-85fa-6d40fad0b6e7

Zobrazit plný text záznamu

PET imaging of disease progression and treatment effects in the experimental autoimmune encephalomyelitis rat model

Autor: Paula Faria, D. de, Vlaming, M.L.H., Copray, S.C.V.M., Tielen, F., Anthonijsz, H.J.A., Sijbesma, J.W.A., Buchpiguel, C.A., Dierckx, R.A.J.O., Hoorn, J.W.A. van der, Vries, E.F.J. de

Publikováno v: Journal of Nuclear Medicine, 8, 55, 1330-1335

The experimental autoimmune encephalomyelitis model is a model of multiple sclerosis that closely mimics the disease characteristics in humans. The main hallmarks of multiple sclerosis are neuroinflammation (microglia activation, monocyte invasion, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::64dad87a782916620283ff2d48f3a068
http://resolver.tudelft.nl/uuid:01f6aa40-bc61-4696-9d49-58d01c02f699

Zobrazit plný text záznamu

P430RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice

Autor: Louwe, M.C., Karper, J.C., Vries, M.R. de, Bastiaansen, A.J.N.M., Hoorn, J.W.A. van der, Willems Van Dijk, K., Rensen, P.C.N., Steendijk, P., Smit, J.W.A., Quax, P.H.A.

Publikováno v: Cardiovascular Research, Suppl 1, 103, S79

Purpose: Toll-like receptor-4 (TLR4), a receptor of the innate immune system, is suggested to have detrimental effects on cardiac function after myocardial infarction (MI). RP105 (CD180) is a TLR4 homolog lacking the intracellular signalling domain t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::cee02f72d481aff7903b23260087cf09
http://resolver.tudelft.nl/uuid:bfaa7671-edbb-40c5-85c1-b00d386061fe

Zobrazit plný text záznamu

The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice

Autor: Hoorn, J.W.A. van der, Jukema, J.W., Havekes, L.M., Lundholm, E., Camejo, G., Rensen, P.C.N., Princen, H.M.G.

Publikováno v: British Journal of Pharmacology, 7, 156, 1067-1075

Background and purpose: We have evaluated the effects of a peroxisome proliferator-activated receptor (PPAR)α/γ agonist on the progression of pre-existing atherosclerotic lesions in APOE*3Leiden.cholesteryl ester transfer protein (E3L.CETP) transge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::aff2bdf867ff2e358fa1b88d2d72dfb5
http://resolver.tudelft.nl/uuid:9ee78a02-3edf-4757-b1d7-244fff8c5937

Zobrazit plný text záznamu

Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin

Autor: Haan, W. de, Vries-van der Weij, J. de, Hoorn, J.W.A. van der, Gautier, T., Hoogt, C.C. van der, Westerterp, M., Romijn, J.A., Jukema, J.W., Havekes, L.M., Princen, H.M.G., Rensen, P.C.N.

Publikováno v: Circulation, 19, 117, 2515-2522

BACKGROUND - Although cholesteryl ester transfer protein (CETP) inhibition is regarded as a promising strategy to reduce atherosclerosis by increasing high-density lipoprotein cholesterol, the CETP inhibitor torcetrapib given in addition to atorvasta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1817c6ca73f77d36f5aa5c03c4426b68
http://resolver.tudelft.nl/uuid:f64e6396-281a-4b2a-957f-f1ad702dbcaa

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání